20220318 147.82 kB 3 <?xml version="1.0" encoding="utf-8" ?> <html lang="en-US" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:fbrx="http://www.fortebiorx.com/20220316" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml"> <head> <title>Form 8-K filed by on 2022-03-18</title> <meta http-equiv="Content-Type" content="text/html" /> </head> <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2022-03-16_to_2022-03-16">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2022-03-16_to_2022-03-16">0001419041</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="#fbrx-20220316.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2022-03-16_to_2022-03-16"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001419041</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-03-16</xbrli:startDate> <xbrli:endDate>2022-03-16</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   <div style="text-align:center">  </div> FORM <ix:nonNumeric name="dei:DocumentType" contextRef="duration_2022-03-16_to_2022-03-16">8-K</ix:nonNumeric>   <div style="text-align:center">  </div> CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2022-03-16_to_2022-03-16" format="ixt:datemonthdayyearen">March 16, 2022</ix:nonNumeric> Date of Report (Date of earliest event reported)   <div style="text-align:center">  </div> <ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2022-03-16_to_2022-03-16">Forte Biosciences, Inc.</ix:nonNumeric> (Exact name of registrant as specified in its charter)   <div style="text-align:center">  </div>   <table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto"> <tr> <td style="width:34%"></td> <td style="vertical-align:bottom"></td> <td style="width:32%"></td> <td style="vertical-align:bottom;width:1%"></td> <td style="width:32%"></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2022-03-16_to_2022-03-16" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></td> <td style="vertical-align:bottom"> </td> <td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2022-03-16_to_2022-03-16">001-38052</ix:nonNumeric></td> <td style="vertical-align:bottom"> </td> <td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2022-03-16_to_2022-03-16">26-1243872</ix:nonNumeric></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style=" text-align: center;margin:auto; vertical-align:top"> (State or other jurisdiction of incorporation)</td> <td style="vertical-align:bottom"> </td> <td style=" text-align: center;margin:auto; vertical-align:top"> (Commission File Number)</td> <td style="vertical-align:bottom"> </td> <td style=" text-align: center;margin:auto; vertical-align:top"> (IRS Employer Identification No.)</td></tr></table>   <table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"> <tr> <td style="width:50%"></td> <td style="vertical-align:bottom;width:1%"></td> <td style="width:48%"></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style=" text-align: center;margin:auto; vertical-align:top"> <ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2022-03-16_to_2022-03-16">3060 Pegasus Park Dr.</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2022-03-16_to_2022-03-16">Building 6</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2022-03-16_to_2022-03-16">Dallas</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2022-03-16_to_2022-03-16" format="ixt-sec:stateprovnameen">Texas</ix:nonNumeric></td> <td style="vertical-align:bottom"> </td> <td style=" text-align: center;margin:auto; vertical-align:bottom"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2022-03-16_to_2022-03-16">75247</ix:nonNumeric></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style=" text-align: center;margin:auto; vertical-align:top">(Address of principal executive offices)</td> <td style="vertical-align:bottom"> </td> <td style=" text-align: center;margin:auto; vertical-align:top">(Zip Code)</td></tr></table> Registrant’s telephone number, including area code: <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2022-03-16_to_2022-03-16">(310)</ix:nonNumeric> <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2022-03-16_to_2022-03-16">618-6994</ix:nonNumeric> Not Applicable (Former name or former address, if changed since last report.)   <div style="text-align:center">  </div> Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:   <table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2022-03-16_to_2022-03-16" format="ixt-sec:boolballotbox">☐</ix:nonNumeric></td> <td style="vertical-align:top"> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</td></tr></table>   <table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2022-03-16_to_2022-03-16" format="ixt-sec:boolballotbox">☐</ix:nonNumeric></td> <td style="vertical-align:top"> Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</td></tr></table>   <table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2022-03-16_to_2022-03-16" format="ixt-sec:boolballotbox">☐</ix:nonNumeric></td> <td style="vertical-align:top"> Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</td></tr></table>   <table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2022-03-16_to_2022-03-16" format="ixt-sec:boolballotbox">☐</ix:nonNumeric></td> <td style="vertical-align:top"> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</td></tr></table> Securities registered pursuant to Section 12(b) of the Act:   <table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto"> <tr> <td style="width:34%"></td> <td style="vertical-align:bottom"></td> <td style="width:32%"></td> <td style="vertical-align:bottom;width:1%"></td> <td style="width:32%"></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> Title of each class</td> <td style="vertical-align:bottom"> </td> <td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> Trading Symbol(s)</td> <td style="vertical-align:bottom"> </td> <td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> Name of each exchange on which registered</td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2022-03-16_to_2022-03-16">Common Stock, par value $0.001 per share</ix:nonNumeric></td> <td style="vertical-align:bottom"> </td> <td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2022-03-16_to_2022-03-16">FBRX</ix:nonNumeric></td> <td style="vertical-align:bottom"> </td> <td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2022-03-16_to_2022-03-16" format="ixt-sec:exchnameen">The Nasdaq Stock Market LLC</ix:nonNumeric></td></tr></table> Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2022-03-16_to_2022-03-16" format="ixt-sec:boolballotbox">☒</ix:nonNumeric> If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <ix:nonNumeric name="dei:EntityExTransitionPeriod" contextRef="duration_2022-03-16_to_2022-03-16" format="ixt-sec:boolballotbox">☒</ix:nonNumeric>      </div></div> <hr style="color:#999999;height:3px;width:100%" /> <div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of Director On March 16, 2022, the Board of Directors (the “Board) of Forte Biosciences, Inc. (the “Company”), upon recommendation of the Nominating and Governance Committee of the Board, appointed Barbara K. Finck, M.D. to the Board, effective March 16, 2022. Dr. Finck will serve as a Class I director, with a term expiring at the annual meeting of stockholders to be held in 2024. Dr. Finck, 75, has served as the acting Chief Medical Officer, Inc. of Coherus BioSciences since August 2019 and prior to that served as Coherus’s Chief Clinical Advisor form January 2019 to August 2019 and Chief Medical Officer from July 2012 to December 2018. Dr. Finck previously served as Senior Vice President and Chief Medical Officer of NKT Therapeutics Inc., a biopharmaceutical company, from September 2010 to July 2012. Prior to that, from June 2007 to June 2010, Dr. Finck served as Senior Vice President of Research and Development and Chief Medical Officer at Osprey Pharmaceuticals U.S.A., Inc., a biopharmaceutical company. Prior to that, Dr. Finck served as an executive for various biopharmaceutical companies. Dr. Finck has served as a member of the board of directors of Reform Biologics, a private biomedical technology company, since March 2021. Dr. Finck has a B.S. in Physiological Psychology from the University of California, Santa Barbara and received her M.D. and post-doctorate training in internal medicine and rheumatology from the University of California, San Francisco School of Medicine. Dr. Finck is board certified in internal medicine. Dr. Finck will be compensated in accordance with the Company’s amended and restated non-employee director compensation policy (the “Policy”). Pursuant to the Policy, Dr. Finck will be entitled to receive $40,000 per year for service as a member of the Board, paid quarterly in arrears on a pro-rata basis. In connection with her appointment to the Board as a non-employee director and pursuant to the Company’s 2021 Equity Incentive Plan and the Policy, Dr. Finck also automatically received a stock option for 50,000 shares of Common Stock of the Company, which will vest in equal monthly installments over a three year period such that the option is fully vested on the third anniversary of the date of grant, subject to Dr. Finck’s continued service on the Board through each applicable vesting date. Dr. Finck has entered into the Company’s standard form of indemnification agreement, a copy of which has been filed as Exhibit 10.1 of the Company’s Registration Statement on Form S-1 (File No. 333-216574), as amended, originally filed on March 9, 2017. There is no arrangement or understanding between Dr. Finck and any other persons pursuant to which Dr. Finck was elected as a director. In addition, Dr. Finck is not a party to any transaction, or series of transactions, required to be disclosed pursuant to Item 404(a) of Regulation S-K. There are no family relationships between Dr. Finck and any of the Company’s directors or executive officers. </div></div> <hr style="color:#999999;height:3px;width:100%" /> <div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.   <table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0"> <tr> <td style="width:45%"></td> <td style="vertical-align:bottom;width:1%"></td> <td style="width:4%"></td> <td style="vertical-align:bottom"></td> <td style="width:3%"></td> <td style="vertical-align:bottom;width:1%"></td> <td style="width:45%"></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td colspan="3" style="vertical-align:bottom;white-space:nowrap"> FORTE BIOSCIENCES, INC.</td></tr> <tr style="font-size:1pt"> <td style="height:12pt"></td> <td style="height:12pt" colspan="2"></td> <td style="height:12pt" colspan="2"></td> <td style="height:12pt" colspan="2"></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Date: March 18, 2022</td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:top;white-space:nowrap"> By:</td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom;white-space:nowrap"> /s/ Antony Riley</td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom;white-space:nowrap"> Antony Riley</td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom;white-space:nowrap"> Chief Financial Officer</td></tr> </table> </div></div> </body></html>